Literature DB >> 21104095

Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates.

Minoru Miyashita1, Takanori Ishida, Kazuyuki Ishida, Kentaro Tamaki, Masakazu Amari, Mika Watanabe, Noriaki Ohuchi, Hironobu Sasano.   

Abstract

We attempted to subclassify triple negative breast cancer (TNBC) cases into subgroups according to clinical outcome or prognosis of TNBC patients using archival specimens. We analyzed 102 Japanese cases of invasive TNBC who underwent surgery between January 1998 and December 2007. The clinicopathological factors and clinical information were retrospectively retrieved from reviewing the charts of the patients. Immunohistochemical staining was performed for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor 1 (EGFR1), CK5/6, CK14, Ki-67, and CD31 for microvessel density (MVD). Median follow-up time of the patients was 68.5 months. Multivariable analysis demonstrated that pathologic node status was the most significantly associated with relapse-free survival (RFS) and breast cancer-specific survival (BCSS) of these patients. Pathological tumor size, basal-like type, Ki-67 labeling index (LI) and MVD were also independently associated with RFS and BCSS. Based on these results, we devised the risk score system reflecting hazard ratios of these prognostic factors above. With this system, TNBC patients in this study were classified into three subgroups (low-risk group: score 0-3, intermediate-risk group: score 4-7 and high-risk group: score 8-10). The significant difference of RFS and BCSS was detected among these three different subgroups of the patients (p < 0.05). We propose the risk score system, which incorporated pathologic nodal status, size of the primary tumor, the presence or absence of basal-like features, Ki-67 LI, and MVD in order to predict postoperative clinical course of the Japanese TNBC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104095     DOI: 10.1007/s00428-010-1009-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  44 in total

1.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

2.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Emmanuelle Charafe-Jauffret; Emilie Mamessier; José Adélaïde; Stéphane Debono; Gilles Houvenaeghel; Dominique Maraninchi; Patrice Viens; Colette Charpin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

5.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 6.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Authors:  Ana Bosch; Pilar Eroles; Rosa Zaragoza; Juan R Viña; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2010-01-08       Impact factor: 12.111

7.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.

Authors:  Y Yamamoto; M Toi; S Kondo; T Matsumoto; H Suzuki; M Kitamura; K Tsuruta; T Taniguchi; A Okamoto; T Mori; M Yoshida; T Ikeda; T Tominaga
Journal:  Clin Cancer Res       Date:  1996-05       Impact factor: 12.531

8.  Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles.

Authors:  Nair Lopes; Bárbara Sousa; Daniella Vieira; Fernanda Milanezi; Fernando Schmitt
Journal:  Histopathology       Date:  2009-11       Impact factor: 5.087

9.  Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

Authors:  B K Linderholm; H Hellborg; U Johansson; G Elmberger; L Skoog; J Lehtiö; R Lewensohn
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

10.  The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

Authors:  Jiyoung Rhee; Sae-Won Han; Do-Youn Oh; Jee Hyun Kim; Seock-Ah Im; Wonshik Han; In Ae Park; Dong-Young Noh; Yung-Jue Bang; Tae-You Kim
Journal:  BMC Cancer       Date:  2008-10-23       Impact factor: 4.430

View more
  13 in total

1.  The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.

Authors:  An Sen Tan; Joe Poe Sheng Yeong; Chi Peng Timothy Lai; Chong Hui Clara Ong; Bernett Lee; Jeffrey Chun Tatt Lim; Aye Aye Thike; Jabed Iqbal; Rebecca Alexandra Dent; Elaine Hsuen Lim; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2019-08-12       Impact factor: 4.064

2.  Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer.

Authors:  M S Al-Moundhri; I Al-Hadabi; K Al-Mawaly; S Kumar; F A R Al-Lawati; G Bhatnager; S Kuruvila; A Al-Hamdani; S M El-Sayed; B Al-Bahrani
Journal:  Med Oncol       Date:  2011-11-03       Impact factor: 3.064

3.  The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings.

Authors:  Beata Biesaga; Joanna Niemiec; Joanna Wysocka; Dorota Słonina; Marek Ziobro
Journal:  Tumour Biol       Date:  2015-12-19

4.  An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.

Authors:  Jing Zhang; Yahong Wang; Quangui Yin; Wei Zhang; Tongxian Zhang; Yun Niu
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

5.  Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation.

Authors:  H Vihervuori; K Korpinen; T A Autere; H Repo; K Talvinen; P Kronqvist
Journal:  Breast Cancer Res Treat       Date:  2022-10-19       Impact factor: 4.624

6.  Endothelial induced EMT in breast epithelial cells with stem cell properties.

Authors:  Valgardur Sigurdsson; Bylgja Hilmarsdottir; Hekla Sigmundsdottir; Agla J R Fridriksdottir; Markus Ringnér; Rene Villadsen; Ake Borg; Bjarni A Agnarsson; Ole William Petersen; Magnus K Magnusson; Thorarinn Gudjonsson
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

7.  P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.

Authors:  Yunbao Pan; Yufen Yuan; Guoshi Liu; Yongchang Wei
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

8.  KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance.

Authors:  Maria A Arafah; Abderrahman Ouban; Omar Z Ameer; Ko Jin Quek
Journal:  Breast Cancer (Auckl)       Date:  2021-05-30

9.  Prognostic and predictive value of Ki-67 in triple-negative breast cancer.

Authors:  Wei Wang; Jiayi Wu; Peifeng Zhang; Xiaochun Fei; Yu Zong; Xiaosong Chen; Ou Huang; Jian-Rong He; Weiguo Chen; Yafen Li; Kunwei Shen; Li Zhu
Journal:  Oncotarget       Date:  2016-05-24

10.  Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.

Authors:  Koichi Kubouchi; Kyosuke Shimada; Takamichi Yokoe; Yutaka Tsutsumi
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.